The deal adds vaccine candidates for respiratory syncytial virus and human metapneumovirus to the French pharmaceutical group ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

No, there’s been a surge of the human metapneumovirus (HMPV). In fact, in mid-March, at the height of the surge, over 19% of all respiratory secretion specimens polymerase chain reaction ...

The Centers for Disease Control and Prevention said human metapneumovirus – also known as HMPV – filled intensive care units with children and seniors this spring.

Maybe it was really a quadruple-demic. A little known and underappreciated virus called human metapneumovirus spiked in the US this spring just after RSV, influenza and Covid-19 died down.

Human metapneumovirus is a virus discovered in 2001 that causes respiratory infection. It falls under the paramyxovirus umbrella, which is "a family of viruses known to cause a wide range of ...